Get the latest news, insights, and market updates on BEAM (Beam Therapeutics Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Analyst Bullish on Beam Therapeutics (BEAM) Over Drug Program Trajectory
Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 13 hot stocks to buy with the highest upside potential. On February 9, Sami Corwin from William Blair maintained a Buy rating on Beam Therapeutics. This maintained rating reinforced the bullish outlook that the analyst previously gave on Beam Therapeutics Inc. (NASDAQ:BEAM) in a January 21 note. […] Feb 19, 2026 - $BEAM
Cathie Wood buys $46 million of tumbling tech stock
Cathie Wood doesn’t give up on her favorite stocks easily. The head of Ark Investment Management actively manages her tech holdings, and her timing often links to market movements. Sometimes Wood buys her top holdings on the way down, hoping for a bargain. That’s what she just did. It’s been a weak ... Feb 16, 2026 - $BEAM
Here is Why Beam Therapeutics (BEAM) Appears so Attractive
Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80. This results in a highly attractive upside potential of more than 197%. Trucchio’s rating is based on several […] Feb 16, 2026 - $BEAM
Assessing Beam Therapeutics (BEAM) Valuation After FDA Expedited Pathway And New Gene‑Editing Patent License
Beam Therapeutics (BEAM) is back in focus after securing an expedited FDA approval pathway for its BEAM-302 program in alpha-1 antitrypsin deficiency, alongside a standby patent license with Kobe University and Bio Palette. See our latest analysis for Beam Therapeutics. The recent FDA expedited pathway and the patent license agreement have arrived after a 27.37% 90 day share price return and a 1 year total shareholder return decline of 13.83%, so recent momentum contrasts with a weaker multi... Feb 16, 2026 - $BEAM
Why Beam Therapeutics (BEAM) Is Up 5.3% After New Gene-Editing IP Deal And FDA Fast Track
Beam Therapeutics recently announced that it secured a standby license with Kobe University and Bio Palette for key gene-editing patents and confirmed the upcoming resignation of board member Carole Ho on February 27, 2026. By reinforcing access to foundational intellectual property while advancing an expedited FDA path for its BEAM-302 program, Beam is addressing two core risks: regulatory uncertainty and long-term IP security. We’ll now examine how the expedited BEAM-302 FDA pathway... Feb 15, 2026 - $BEAM
H.C. Wainwright Reiterated Buy on Beam Therapeutics (BEAM) After BEAM-302 FDA Expedited Approval
Beam Therapeutics Inc. (NASDAQ:BEAM) ranks among the best innovative stocks to buy according to Wall Street analysts. H.C. Wainwright reiterated a Buy rating and $80 price target for Beam Therapeutics Inc. (NASDAQ:BEAM) on January 15, citing the company’s developments over its BEAM-302 therapy. This comes after Beam announced that it reached an agreement with the […] Feb 15, 2026 - $BEAM
Bernstein Maintains an Outperform Rating on Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (NASDAQ:BEAM) is among the Growth Stock Portfolio: 12 Stock Picks By Cathie Wood. On January 7, 2026, TheFly reported that Bernstein maintained its Outperform rating. It increased its price objective for Beam Therapeutics Inc. (NASDAQ:BEAM) from $37 to $41. The company’s Alpha-1 Antitrypsin Deficiency program received a favorable regulatory update before the […] Jan 29, 2026 - $BEAM
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple